We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.19 | 0.75% | 25.45 | 25.54 | 25.20 | 25.33 | 46,480,354 | 01:00:00 |
From Apr 2019 to Apr 2024
AstraZeneca PLC said it has agreed to sell part of its antibiotics business to Pfizer Inc. for up to $1.575 billion plus royalties.
Under the terms of the deal Pfizer will pay Astra $550 million upfront plus an unconditional $175 million in January 2019. Then, depending on the progress and commercial success of the drugs in question, it will pay a further $850 million plus royalties.
The deal involves three already-approved antibiotics and two drugs in clinical trials. It will give Pfizer the right to sell those drugs in most markets outside the U.S.
It doesn't involve Astra's portfolio of biological anti-infective drugs, or the business it spun out last year to focus on the development of innovative anti-infectives.
Write to Denise Roland at Denise.Roland@wsj.com
(END) Dow Jones Newswires
August 24, 2016 04:15 ET (08:15 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
